Published in Arq Neuropsiquiatr on March 01, 1983
Hydrocephalus in neurocysticercosis. Childs Nerv Syst (2011) 1.70
Diagnosis of cysticercosis in endemic regions. The Cysticercosis Working Group in Peru. Lancet (1991) 1.63
Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil. J Neurol Neurosurg Psychiatry (1997) 1.34
Immunological and molecular diagnosis of cysticercosis. Pathog Glob Health (2012) 1.20
Proposed diagnostic criteria for neurocysticercosis. Neurology (2001) 9.15
Calcific neurocysticercosis and epileptogenesis. Neurology (2004) 2.57
Treatment of neurocysticercosis: current status and future research needs. Neurology (2006) 2.41
Calcified neurocysticercotic lesions and postsurgery seizure control in temporal lobe epilepsy. Neurology (2000) 1.25
Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Arch Neurol (1992) 1.10
Using the National Institute of Health Stroke Scale to predict dysphagia in acute ischemic stroke. Cerebrovasc Dis (2012) 1.00
Cysticercosis of the central nervous system. II. Spinal cysticercosis. Arq Neuropsiquiatr (1994) 0.94
Calcified cysticercotic lesions and intractable epilepsy: a cross sectional study of 512 patients. J Neurol Neurosurg Psychiatry (2006) 0.88
Chagasic meningoencephalitis with detection of Trypanosoma cruzi in the cerebrospinal fluid of an immunodepressed patient. J Trop Med Hyg (1994) 0.87
Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. Braz J Med Biol Res (2003) 0.87
The gene for Machado-Joseph disease maps to the same 3-cM interval as the spinal cerebellar ataxia 3 gene on chromosome 14q. Neurobiol Dis (1994) 0.86
Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. Chirality (1999) 0.85
Cognitive performance of patients with mesial temporal lobe epilepsy and incidental calcified neurocysticercosis. J Neurol Neurosurg Psychiatry (2005) 0.83
[Neurocysticercosis: contribution of autopsies in the consolidation of mandatory notification in Ribeiräo Preto-SP,Brazil]. Arq Neuropsiquiatr (1998) 0.83
Simultaneous determination of albendazole sulfoxide enantiomers and albendazole sulfone in plasma. J Chromatogr B Biomed Sci Appl (1998) 0.82
Characterisation of the unstable expanded CAG repeat in the MJD1 gene in four Brazilian families of Portuguese descent with Machado-Joseph disease. J Med Genet (1995) 0.82
Interleukin-18 and interferon-gamma polymorphisms are implicated on proviral load and susceptibility to human T-lymphotropic virus type 1 infection. Tissue Antigens (2012) 0.81
Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. Chirality (2004) 0.81
[Epilepsy and chronic Chagas disease]. Arq Neuropsiquiatr (1981) 0.80
Albendazole therapy for neurocysticercosis. Neurology (1998) 0.78
Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450. Braz J Med Biol Res (2002) 0.77
Determination of albendazole metabolites in plasma by HPLC. J Anal Toxicol (1994) 0.75
Tropical spastic paraparesis in Brazil. Lancet (1991) 0.75
[Experimental acute Chagas' disease: parasitism of the hypothalamus]. Arq Neuropsiquiatr (1971) 0.75
Moyamoya disease in Brazil. Acta Neurol Scand (1997) 0.75
Enantioselective analysis of albendazole sulfoxide in cerebrospinal fluid by capillary electrophoresis. Electrophoresis (2001) 0.75
[Chronic nervous form of Chagas disease: clinical course and anatomopathology of a case followed-up for 20 years]. Arq Neuropsiquiatr (1993) 0.75
Enantioselective analysis of albendazole sulfoxide in plasma using the chiral stationary phase. Chirality (1997) 0.75
[Experimental Chagas' disease in rat parasitism of the nucleus of the 3rd cranial pair]. Rev Inst Med Trop Sao Paulo (1972) 0.75
Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis. Braz J Med Biol Res (2005) 0.75
[Cryptococcus meningitis: clinical course, development and histopathologic aspects depending on the predisposing factors]. Rev Soc Bras Med Trop (1991) 0.75
[Myelopathy caused by histoplasmosis: report of a case]. Arq Neuropsiquiatr (1981) 0.75
[Neurologic and cerebrospinal fluid study in patients with the chronic form of Chagas' disease]. Arq Neuropsiquiatr (1972) 0.75